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There is no report of exhaled NO (eNO) in subjects with different phenotypes of a1-anti-trypsin (AAT) deficiency.
Exhaled nitric oxide was evaluated by means of single-breath chemiluminescence analysis (fractional exhaled
concentration at the plateau level [plFENO]) in 40 patients with AAT deficiency. Patients were divided according to
the protease inhibitor (Pi) phenotype: PiMZ/MS, n=25; PiSZ n=6; PiZZ, n=9. Nineteen healthy subjects served
as controls. Levels of eNO in PiZZ patients were also compared with those of subjects, without AAT deficiency
(PiMM), matched for diagnosis, sex, age, smoking habit and forced expiratory volume in 1 sec (FEV1). In AAT
deficiency subjects airway hyper-responsiveness to methacholine (PD20 FEV1) was also assessed.
plFENO was significantly lower in the PiZZ group (4?5+1?4 ppb) than in matched PiMM subjects (8?2+3?8 ppb),
in healthy controls (9?3+2?8 ppb) and in patients of other phenotypes. Dynamic lung volumes and DLCO were
significantly lower in PiZZ than in other AAT-deficient patients. Bronchial hyper-responsiveness was not different
among AAT phenotypes.
These results suggest that eNO may be significantly reduced in PiZZ as compared to healthy control subjects and
to AAT subjects with other phenotypes, independent of the level of airway obstruction. Whether, at least
potentially, eNO may be considered as an early marker of lung involvement in AAT deficiency must be confirmed
with studies on larger number of subjects.
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a1-anti-trypsin (AAT) deficiency is an autosomal recessive
disorder caused by mutant variants of the human protease
inhibitor (Pi) system locus on chromosome 14 (1). In
subjects with AAT deficiency the severity of lung disease
and the rate of decline in lung function vary markedly (2);
the genetic profile affects susceptibility to lung destruction
(3). In AAT deficiency, chronic obstructive pulmonary
disease (COPD) has been found to be associated to the PiZ
homozygous phenotype (PiZZ) (2–3), whereas airway
hyper-responsiveness has been found to be more frequently
associated to subjects with PiM heterozygous phenotypes
(PiMS/MZ) (4).
Nitric oxide (NO) may regulate vascular and airway tone
in the lung, thus influencing lung function (5–7). Exhaled
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0954-6111/01/060520+06 $35?00/0humans (9). Increased eNO has been demonstrated in
bronchial asthma (10), whereas decreased levels were found
in the most severe stages of chronic diseases resulting in
pulmonary hypertension such as chronic heart failure (11),
COPD (12,13) and systemic sclerosis (14).
Recently, polymorphic variants of the constitutive
endothelial nitric oxide synthase (cNOS) have been found
to be associated with lung emphysema in subjects with
AAT deficiency, suggesting a role of NO in the pathogen-
esis of the lung disease of these subjects (15). However,
there is no report of eNO measurement in AAT deficient
subjects with different phenotypes and related lung function
derangements (if any). In this study eNO was compared in
subjects with different phenotypic expression of AAT
deficiency. PiZZ were also compared with matched subjects
without AAT deficiency.
Materials and methods
Patients gave their informed consent to participate into the
study, which was approved by the Ethical Committees of
the Salvatore Maugeri Foundation IRCCS and the Uni-# 2001 HARCOURT PUBLISHERS LTD
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Declaration of Helsinki.
SUBJECTS
Forty subjects with AAT deficiency, included in the Italian
National Register (16) and attending the Chest Clinic of the
Institute of Internal Medicine at the University of Brescia
were studied. Diagnosis of AAT deficiency was confirmed
by evaluation of Pi phenotypes. According to the pheno-
type, subjects were divided into three groups: PiMZ/MS,
PiSZ and PiZZ. Diagnosis of COPD and asthma were made
according to the standard criteria (17,18). Atopy was
defined by positive skin tests and/or increased level of
specific serum IgE. Pulmonary emphysema was confirmed
on the basis of lung function tests, DLCO and computed
tomography (CT) scan. Bronchiectases were assessed by
ultra-thin CT scan. At the time of the study all the subjects
were in a stable condition and free from acute exacerbation
for at least 4 weeks. Fourteen subjects used regular
treatment with inhaled bronchodilators. No patient was
on systemic or inhaled steroids. One PiZZ subject suffered
from chronic respiratory insuciency and had been on
long-term oxygen therapy for 1 year. The demographic,
anthropometric and clinical characteristics of the patients
according to the phenotypes are shown in Table 1. PiZZ
subjects were compared with subjects without AAT
deficiency (PiMM), matched for associated diagnosis, sex,
age (+5 years), smoking habits, post-bronchodilator forced
expiratory volume in 1 sec (FEV1) (+12% predicted) and
lack of use of inhaled steroids. Furthermore 19 age-related
healthy volunteers (11 male, age: 45+8 years) were studied
as controls for eNO measurement in our laboratory.
MEASUREMENTS
Phenotypes were determined using dried blood specimens
as previously described (19,20). Serum AAT was deter-
mined by radial immunodiffusion (21).
Static and dynamic volumes were measured by means of
nitrogen wash-out method and pneumotachograph with
volume integrator (CAD/NET System; Medical Graphic
Corporation St. Paul, MN, U.S.A.), according to the
European Respiratory Society (ERS) standard procedure
(22). Forced vital capacity (FVC) manoeuvres were
performed before and after the administration of 200mcg
of inhaled salbutamol. DLCO was assessed by means of a
pulmonary diagnostic system (PF/DX system, Medical
Graphic Corporation) with patients in the sitting position.
The predicted values according to Quanjer (23) were used.
Methacholine challenge was performed according to the
guidelines (24) and the cumulative dose at which FEV1 fell
by 20% from the post-saline value (PD20FEV1) was
calculated.
Measurements of eNO were performed in the Lung
Function Unit of the Scientific Institute of Gussago,
Salvatore Maugeri Foundation, as previously described
(12,13), blind to the patient’s clinical and functional status.
Briefly, subjects were asked to discontinue bronchodilatorsand to abstain from alcohol and caffeine at least 12 h and
from food at least 4 h before the assessment. Exhaled NO
was assessed on-line by means of a high-resolution
(0?3 ppb) chemiluminescence analyser (LR 2000 series,
Logan Research, Kent, U.K.). An internal restrictor in
the breathing circuit allowed for expiration against a
resistance in order to keep the soft palate closed and to
prevent contamination of the exhaled air with nasal NO; a
single-breath vital capacity (VC) manoeuvre at constant
flow (50ml sec71) was performed as recommended (25).
The analyser was daily calibrated using a certified NO
mixture (96 ppb) in nitrogen (Messer S.p.A., Collegno,
Italy). Ambient air was monitored for NO concentration
before starting evaluations. Measurements were only taken
when ambient NO was below 40 ppb (26). Fractional
exhaled NO concentration at the plateau level (plFENO) was
obtained from the eNO curve as previously described
(12,13). The mean value of three reproducible measure-
ments was considered for analysis.
ANALYSIS
Data are given as frequencies and/or means + standard
deviation (SD). Analysis of differences was performed by a
Kruskal–Wallis one-way ANOVA. The Mann–Whitney
U-test for non-parametric variables was used when appro-
priate. Chi-square and Cochran’s Q analysis was used to
test the categorized variables. Intra-patient FENO differences
were analysed by ANOVA for repeated measures with
Huynh–Feldt correction. As no significant within-subject
difference was found, the mean FENO value of three
consecutive measurements was taken into account. Spear-
man correlation coecients were calculated among all the
considered variables. A P-value less than 0?05 was
considered to be statistically significant.
Results
CLINICAL STATUS
Anthropometric, demographic and clinical characteristics
of the AAT subjects are shown in Table 1. Most of the
subjects presented the PiM phenotypes. As expected, serum
AAT levels were significantly lower in PiZZ subjects (1–3).
No differences in the frequency distribution of smoking
habit or atopy were found among the groups. A diagnosis
of COPD and/or emphysema was found in most of the
PiZZ subjects but only in one PiMZ subject. Among six
COPD patients in the PiZZ group, two (33%) and four
(67%) were in ATS stage I and III, respectively. Asthma
was evenly represented in all groups.
LUNG FUNCTION AND AIRWAY
HYPER-RESPONSIVENESS
Table 2 shows static and dynamic volumes, DLCO and
PD20FEV1. Mean FEV1 and DLCO were significantly lower
in PiZZ than in other phenotypes. No difference in static
522 M. MALERBA ET AL.lung volumes was found among different phenotypes. DLCO
significantly correlated with FEV1 (r=0?74, P50?0001).
Methacholine challenge was denied in three out of nine
PiZZ subjects due to a baseline FEV1 lower than 1 l. Lack
of hyper-responsiveness as assessed by reaching the
maximal cumulative methacholine dose of 4mg was
recorded in 18 out of 25 (72%) PiMZ/MS, five out of six
(83%) PiSZ and four out of six (67%) PiZZ subjects
respectively, without any significant difference among
phenotypes. Mean PD20FEV1 did not significantly differ
among these groups (Table 2).TABLE 1. Demographic, anthropometric and clinical char-
acteristics
PiMZ/MS PiSZ PiZZ
No. of subjects (%) 25 (62) 6 (15) 9 (23)
Gender (M/F) 19/6 2/4 3/6
Age (years) 38+17 45+11 44+11
AAT level (mg dl71) 101+20 74+29 33+2*
Atopy (%) 15 (60) 4 (66) 4 (44)
Smoking history
Actual number (%) 7 (28) 1 (17) 4 (44)
Never (%) 14 (56) 2 (33) 1 (12)
Former (%) 4 (16) 3 (50) 4 (44)
Diagnosis
COPD/emphysema (%) 1 (4) 0 (0) 6 (67)
Bronchiectasis (%) 2 (8) 0 (0) 0 (0)
Asthma (%) 3 (12) 1 (17) 1 (11)
Liver disease (%) 2 (8) 0 (0) 1 (11)
Healthy (%) 17 (68) 5 (83) 1 (11)
*P50?001 vs. other groups (post-hoc test).
AAT: Serum a1-anti-trypsin.
TABLE 2. Lung function, diffusion capacity and airway hyper-re
PiMZ/MS P
No. 25
FEV1 (%pred.) 114+14 133+
VC (%pred.) 107+13 125
FEV1/VC (%) 105+7 107
RV (%pred.) 121+33 115
TLC (%pred.) 112+15 120
DLCO (%pred.) 111+20 103
PD20FEV1 (mg) 3?31+1?14 3?18+
*P50?01 vs. PiMZ/MS (post-hoc test); {P50?05 vs. PiMZ/MS
vs. PiSZ (post-hoc test).
FEV1: forced expiratory volume in 1 sec; VC: vital capacity; R
diffusion capacity to carbon monoxide; PD20FEV1: cumulative
from the post-saline value.EXHALED NO
Exhaled NO was detectable in all the subjects, plFENO
variation coecient (SD/mean %) of intra-patient
measurements was 5+2% (range, 2–10%). Figure 1
shows plFENO individual and mean values in
different groups. plFENO was significantly lower in PiZZ
than in both subjects with other phenotypes and
healthy controls (n=19, see Methods). Table 3 shows
the anthropometric, demographic, functional characteris-
tics and plFENO of individual PiZZ patients and their
respective matched control PiMM subjects. eNO was
significantly lower in PiZZ patients than in matched
controls.
There was no significant difference in FENO values
between atopic and non-atopic patients or between smokers
and non-smokers. There was no significant relationship
between FENO and PD20FEV1, post-bronchodilator FEV1
or DLCO.sponsiveness
iSZ PiZZ P ANOVA
6 9
11* 64+39{{ 0?006
+8* 94+29{ 0?025
+8 68+33*{ 0?043
+41 127+40 0?940
+11 109+22 0?276
+12 72+34*} 0?01
1?27 2?99+1?60 0?951
(post-hoc test); {P50?005 vs. PiSZ (post-hoc test); }P50?05
V: residual volume, TLC: total lung capacity; DLCO: lung
dose of inhaled methacholine causing a FEV1 20% falling
FIG. 1. Individual and mean values of plFENO in the study
groups (*P=0?04 vs. PiMZ/MS; {P=0?015 vs. PiSZ;
{P=0?0002 vs. controls).
TABLE 3. Characteristics of the PiZZ-and PiMM-matched subjects
Pair Sex Smoking Inhaled steroids Phenotype Age FEV1 (% predicted) plFENO (ppb)
1 F No No PiZZ
PiMM
35
40
128
118
6?5
7?9
2 F Yes No PiZZ
PiMM
36
39
105
100
3?8
12?1
3 F No No PiZZ
PiMM
35
39
105
99
6?0
12?1
4 F Yes No PiZZ
PiMM
28
33
68
79
2?9
12?7
5 F No No PiZZ
PiMM
48
53
52
62
3?5
10?1
6 F Yes No PiZZ
PiMM
58
61
38
47
4?5
2?9
7 F Yes No PiZZ
PiMM
54
55
32
28
2?6
2?7
8 F No No PiZZ
PiMM
58
62
26
30
6?0
6?5
9 F No No PiZZ
PiMM
40
45
24
35
5?0
7?3
Mean+SD PiZZ
PiMM
43+11
47+10
64+39
66+34
4?5+1?4
8?2+3?8
P 0?426 0?894 0?014
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To our knowledge, this is the first study to report levels of
eNO in subjects with different phenotypes of AAT
deficiency and to relate them with lung function. When
compared with AAT subjects having other phenotypes and
with matched subjects without AAT with similar airway
obstruction, PiZZ subjects showed significantly reduced
eNO levels, without any significant correlation with lung
function or airway hyper-responsiveness.
Confirming previous reports (2,27,28), our PiZZ subjects
showed a greater incidence of COPD and lower mean levels
of FEV1 and DLCO than the other AAT phenotypes.
PiZZ subjects of this study showed significantly reduced
eNO levels in comparison with other phenotypes and with
matched controls. Despite conflicting results (29), reduced
FENO has been reported to be associated with the severity
of airway obstruction in a stable population of COPD
patients (12) and with acute induced bronchoconstriction in
asthmatic subjects (30). In addition, in severe COPD
patients (ATS class III) cor pulmonale has been shown to
be associated with lower eNO production (13).
Reduced levels of eNO in our PiZZ patients might well
be ascribed to severity of associated COPD and related
clinical consequences. Indeed the mean FENO level of PiZZ
patients was similar to that reported in most severe COPD
patients (13). Nevertheless, some points should be ad-
dressed: (i) less than half of these subjects (three out of nine:
33%) showed a FEV1 lower than 35% predicted; (ii)although in this study pulmonary artery pressure was not
directly assessed, none of the patients had clinical,
radiological or EKG signs of cor pulmonale; (iii) in the
whole population of AAT subjects, FENO did not
significantly correlate with either FEV1 or DLCO. Further-
more PiZZ subjects showed lower levels of FENO when
compared with associated diagnosis, age, sex, smoking
habit, and FEV1-matched PiMM subjects. A multiple
logistic regression analysis would have been more appro-
piate, due to the number of potential confounders in eNO
reading; however, the small number of PiZZ subjects makes
this approach dicult to apply. Our findings only suggest
that, in AAT deficiency, eNO should not be considered as a
merely feature of severity of associated lung disease.
Endogenous NO has been hypothesized to have a role in
airway tone modulation (31,32). With the limitation of the
small number of subjects, in our study different phenotypes
did not show any difference in airway hyper-responsiveness
(Table 2) or in prevalence of asthma (Table 1). In the whole
AAT-deficient population of our study no correlation was
found between FENO and PD20FEV1, independent of the
atopic status. This lack of correlation may suggest that in
subjects with AAT deficiency, differently from asthmatic
patients (30), NO is less involved in the pathogenesis of
airway hyper-responsiveness . Conversely, when consider-
ing only five AAT deficient and asthmatic subjects (Table 1)
a significant inverse correlation (r=70?77, P50?001)
between FENO and PD20FEV1 was found, indicating that,
differently from severe asthmatic individuals (33), in AAT
524 M. MALERBA ET AL.subjects eNO may have no protective role in airway hyper-
responsiveness.
In conclusion, exhaled NO is significantly reduced in
PiZZ as compared with healthy control subjects and with
subjects with other phenotypes of AAT deficiency, inde-
pendent of airway obstruction. Whether eNO might be
considered as an early marker of lung involvement, needing
to be specifically monitored, should be evaluated in
longitudinal studies on greater number of these PiZZ
subjects.
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